open access

Vol 86, No 6 (2018)
CASE REPORTS
Published online: 2018-12-30
Submitted: 2018-10-19
Accepted: 2018-11-24
Get Citation

Development of bronchiectasis during long-term rituximab treatment for rheumatoid arthritis

Víctor A Santos, Gabriel J. Tobón, Carlos A Cañas
DOI: 10.5603/ARM.a2018.0050
·
Pubmed: 30594999
·
Adv Respir Med 2018;86(6):310-313.

open access

Vol 86, No 6 (2018)
CASE REPORTS
Published online: 2018-12-30
Submitted: 2018-10-19
Accepted: 2018-11-24

Abstract

Here the cases of three female patients who received long-term rituximab treatment for seropositive, erosive and deforming rheumatoid arthritis was reported. After rituximab treatment, they presented with recurrent sinusitis and pneumonia, followed by the subsequent development of bronchiectasis. A temporal relationship between rituximab treatment and the onset of respiratory complications was exposed as a possible pathogenic mechanism.

Abstract

Here the cases of three female patients who received long-term rituximab treatment for seropositive, erosive and deforming rheumatoid arthritis was reported. After rituximab treatment, they presented with recurrent sinusitis and pneumonia, followed by the subsequent development of bronchiectasis. A temporal relationship between rituximab treatment and the onset of respiratory complications was exposed as a possible pathogenic mechanism.

Get Citation

Keywords

bronchiectasis, rheumatoid arthritis, rituximab, sinusitis

About this article
Title

Development of bronchiectasis during long-term rituximab treatment for rheumatoid arthritis

Journal

Advances in Respiratory Medicine

Issue

Vol 86, No 6 (2018)

Pages

310-313

Published online

2018-12-30

DOI

10.5603/ARM.a2018.0050

Pubmed

30594999

Bibliographic record

Adv Respir Med 2018;86(6):310-313.

Keywords

bronchiectasis
rheumatoid arthritis
rituximab
sinusitis

Authors

Víctor A Santos
Gabriel J. Tobón
Carlos A Cañas

References (20)
  1. Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis. Nat Clin Pract Rheumatol. 2007; 3(2): 86–95.
  2. Storz U. Rituximab: how approval history is reflected by a corresponding patent filing strategy. MAbs. 2014; 6(4): 820–837.
  3. Bonilla-Abadía F, Coronel Restrepo N, Tobón GJ, et al. Rituximab for remission induction and maintenance in refractory systemic lupus erythematosus. Autoimmune Dis. 2014; 2014: 731806.
  4. Van Allen EM, Miyake T, Gunn N, et al. Off-label use of rituximab in a multipayer insurance system. J Oncol Pract. 2011; 7(2): 76–79.
  5. Kang HJ, Park JS, Kim DW, et al. Adverse pulmonary reactions associated with the use of monoclonal antibodies in cancer patients. Respir Med. 2012; 106(3): 443–450.
  6. Bitzan M, Anselmo M, Carpineta L. Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature. Pediatr Pulmonol. 2009; 44(9): 922–934.
  7. Biehn SE, Kirk D, Rivera MP, et al. Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma. Hematol Oncol. 2006; 24(4): 234–237.
  8. Tonelli AR, Lottenberg R, Allan RW, et al. Rituximab-induced hypersensitivity pneumonitis. Respiration. 2009; 78(2): 225–229.
  9. Heresi GA, Farver CF, Stoller JK. Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: case report and review of the literature. Respiration. 2008; 76(4): 449–453.
  10. Farhat L, Dara J, Duberstein S, et al. Secondary Hypogammaglobulinemia After Rituximab for Neuromyelitis Optica: A Case Report. Drug Saf Case Rep. 2018; 5(1): 22.
  11. Diaz JC, Vallejo S, Cañas CA. Drug-induced lupus in anti-TNF-alpha therapy and its treatment with rituximab. Rheumatol Int. 2012; 32(10): 3315–3317.
  12. Barker AF. Bronchiectasis. N Engl J Med. 2002; 346(18): 1383–1393.
  13. Ramakrishnan VR, Ferril GR, Suh JD, et al. Upper and lower airways associations in patients with chronic rhinosinusitis and bronchiectasis. Int Forum Allergy Rhinol. 2013; 3(11): 921–927.
  14. King P, Holdsworth S, Freezer N, et al. Bronchiectasis. Intern Med J. 2006; 36(11): 729–737.
  15. Solanki T, Neville E. Bronchiectasis and rheumatoid disease: is there an association? Br J Rheumatol. 1992; 31(10): 691–693.
  16. Bamji A, Cooke N, Bamji A, et al. Association between rheumatoid arthritis and chronic bronchial suppuration. Ann Rheum Dis. 1984; 43(6): 856–21.
  17. McMahon MJ, Swinson DR, Shettar S, et al. Bronchiectasis and rheumatoid arthritis: a clinical study. Ann Rheum Dis. 1993; 52(11): 776–779.
  18. Shadick NA, Fanta CH, Weinblatt ME, et al. Bronchiectasis. A late feature of severe rheumatoid arthritis. Medicine (Baltimore). 1994; 73(3): 161–170.
  19. Chung SD, Chen PY, Lin HC, et al. Comorbidity profile of chronic rhinosinusitis: a population-based study. Laryngoscope. 2014; 124(7): 1536–1541.
  20. Cooper N, Arnold DM. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol. 2010; 149(1): 3–13.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl